ID   ELF-153
AC   CVCL_2031
SY   Elf-153; ELF153
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473443
DR   Cosmic; 787427
DR   Cosmic; 975245
DR   Cosmic; 1012064
DR   Cosmic; 1281310
DR   Cosmic; 1465954
DR   Cosmic; 2306197
DR   DSMZ; ACC-693
DR   DSMZCellDive; ACC-693
DR   Wikidata; Q54832241
RX   CelloPub=CLPUB00037;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7519473;
RX   PubMed=7488550;
RX   PubMed=16408098;
RX   PubMed=31160637;
CC   Part of: LL-100 blood cancer cell line panel.
CC   Characteristics: CSF2 dependent.
CC   Doubling time: 36 hours (PubMed=7488550; PubMed=7519473); ~40-60 hours (DSMZ=ACC-693).
CC   HLA typing: A*01:01:01,02:01:01; B*08:01:01,35:01:01; C*07:01:01,07:01:01; DPA1*01:03:01,02:01:01; DPB1*14:01:01,04:02:01; DQB1*03:01:01,03:01:01; DRA*01:01:01,01:01:01; DRB1*09:01:02,11:01:01 (DSMZCellDive=ACC-693).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ; Genomics_Center_BCF_Technion
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D10S1248: 13,14
ST   D12S391: 19
ST   D13S317: 8
ST   D16S539: 12,13
ST   D18S51: 12,15
ST   D19S433: 13,14.2 (Genomics_Center_BCF_Technion)
ST   D19S433: 13,15 (DSMZ)
ST   D1S1656: 15.3,16
ST   D21S11: 31,32.2
ST   D22S1045: 16
ST   D2S1338: 18,25
ST   D2S441: 11,14
ST   D3S1358: 17,18 (Genomics_Center_BCF_Technion)
ST   D3S1358: 18 (DSMZ)
ST   D5S818: 11
ST   D7S820: 9,10 (DSMZ)
ST   D7S820: 9.3 (Genomics_Center_BCF_Technion)
ST   D8S1179: 12,13
ST   FGA: 19,23
ST   Penta D: 12,13
ST   Penta E: 12,14
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 19
//
RX   CelloPub=CLPUB00037;
RA   Freund M., Kleine H.-D., Lux E., Exeriede G., Hanauske A.-R.,
RA   Herbst H., Vainchenker W., Schweigerer L., Fonatsch C., Poliwoda H.;
RT   "ELF-153: a novel cell line derived from a patient with acute
RT   myelofibrosis and AML.";
RL   Blut 61:128-128(1990).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7519473; DOI=10.1182/blood.V84.4.1085.1085;
RA   Mouthon M.-A., Freund M., Titeux M., Katz A., Guichard J.,
RA   Breton-Gorius J., Vainchenker W.;
RT   "Growth and differentiation of the human megakaryoblastic cell line
RT   (ELF-153): a model for early stages of megakaryocytopoiesis.";
RL   Blood 84:1085-1097(1994).
//
RX   PubMed=7488550;
RA   Hassan H.T., Hanauske A.-R., Lux E., Kleine H.-D., Freund M.;
RT   "A new fibroblast growth stimulating activity from the human
RT   megakaryoblastic leukaemia cell line ELF-153: in vitro and in vivo
RT   findings.";
RL   Int. J. Exp. Pathol. 76:361-367(1995).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//